INmune Bio, Inc.
INMBHealthcare|Biotechnology|US
$1.13
-0.04 (-3.83%)
DCF Value
$0.76
Tangible Book / Share
$0.65
Cash / Share
$0.59
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04370236 INB03 for the Treatment of Pulmonary Complications From COVID-19 | COVID-19 | P2P3 | Terminated | 79 | RCT, Double-blind | INB03, Placebo |
| NCT05522387 An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | Alzheimer Disease, Dementia | P2 | Terminated | 11 | Open-label | XPro1595 |
| NCT06056791 Study of INKmune in Patients With mCRPC (CaRe Prostate) | Cancer, Metastatic Castration-resistant Prostate Cancer | P1P2 | Completed | 12 | Open-label | INKmune |
| NCT05318976 A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | Alzheimer Disease, Dementia | P2 | Completed | 207 | RCT, Double-blind | XPro1595, Placebo |
| NCT05321498 Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation | Mild Cognitive Impairment (MCI), Alzheimer Disease | P2 | Withdrawn | — | RCT, Double-blind | XPro1595, Placebo |
| NCT03943264 A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's | Alzheimer Disease | P1 | Completed | 20 | Open-label | XPro1595 |
| NCT05933070 A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML | Cancer, MDS-EB | P1 | Terminated | 2 | Open-label | INKmune |